Transcriptome-Inferred metabolic subtypes define prognostic and immune ecosystems in osteosarcoma at single-cell resolution - Scorecard - MDSpire

Transcriptome-Inferred metabolic subtypes define prognostic and immune ecosystems in osteosarcoma at single-cell resolution

  • By

  • Li Hu

  • Dingsheng Zhang

  • Boyang Wang

  • Qian Liu

  • Xingyu Liao

  • Feiyang Qi

  • Linxi Chen

  • Huimin Liu

  • Zhiqing Zhao

  • Haijie Liang

  • Xingyu Liu

  • Zhiye Du

  • Rui Yang

  • Yi Yang

  • Yang Wang

  • Jichuan Wang

  • June 18, 2026

  • 0 min

Share

Clinical Scorecard: Metabolic Subtypes Inferred from Transcriptome Analysis Reveal Prognostic and Immune Landscapes in Osteosarcoma at the Single-Cell Level

At a Glance

CategoryDetail
Condition
Key MechanismsMetabolic heterogeneity characterized by distinct subtypes: Cholesterogenic (C1), Redox-Catabolic (C2), OXPHOS-Active (C3) with clinical implications.
Target Population
Care Setting

Key Highlights

  • Integration of bulk transcriptomes and single-cell RNA sequencing enhances understanding of metabolic states.

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider metabolic subtype classification for therapeutic hypothesis generation, including specific strategies.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Metabolic subtypes may inform treatment strategies and risk stratification, influencing specific therapeutic decisions.

        Clinical Best Practices

        • Incorporate metabolic profiling into routine assessments of osteosarcoma.
        • Utilize single-cell analysis to clarify cellular origins of metabolic states.
        • Apply consensus clustering for subtype discovery in clinical research.
        • Encourage future research to explore therapeutic implications of metabolic subtypes.

        Related Resources & Content

          Original Source(s)

          Transcriptome-Inferred metabolic subtypes define prognostic and immune ecosystems in osteosarcoma at single-cell resolution

          • by Li Hu, Dingsheng Zhang, Boyang Wang, Qian Liu, Xingyu Liao, Feiyang Qi, Linxi Chen, Huimin Liu, Zhiqing Zhao, Haijie Liang, Xingyu Liu, Zhiye Du, Rui Yang, Yi Yang, Yang Wang, Jichuan Wang

          • June 18, 2026

          Related Content

          ABO gene polymorphisms: a molecular bridge linking disease susceptibility to therapeutic outcomes

          Targeting RAC1 in glioblastoma: prognostic value, immune landscape, and small molecule therapeutic potential

          Malignant transformation of uterine serosal endometriosis to clear cell carcinoma in a postmenopausal patient: a rare case report